Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

Barron’s 2024 Healthcare Roundtable panelists make the case for 21 healthcare companies of all stripes, including Humana, ...

On Thursday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $909.32 which represents a decrease of $-15.24 or -1.65% from the prior close of $924.56. The stock opened at $920.26 and ...

The diet and weight-loss brand, which has struggled to adapt in the Ozempic era, is losing its latest chief executive after ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

WW International Inc. ousted Chief Executive Officer Sima Sistani after a tumultuous two-and-a-half year tenure at the diet ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...

The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam.Most Read from ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...